Tranexamic Acid in Suspected Hemothorax: Current Evidence
Tranexamic acid (TXA) is NOT recommended for hemothorax management in hemodynamically stable patients undergoing chest-tube drainage, as the most recent 2025 thoracic trauma guidelines make no mention of TXA for this indication and specifically note that thrombolytic agents in the pleural cavity are associated with delayed resolution, increased costs, and increased complications. 1
Evidence Analysis
What the Guidelines Say About Hemothorax Management
The 2025 WSES-AAST thoracic trauma guidelines provide comprehensive management algorithms for hemothorax but completely omit any role for tranexamic acid 1. The guideline explicitly addresses:
- Drainage strategy: Hemothorax ≥500 ml should be drained within 72 hours using large-bore chest tubes (28-40Fr)
- Surgical indications: Hemodynamic instability, >1500 mL initial output, or >200 mL/h over 3 consecutive hours
- What NOT to use: "Few data exist about the use of thrombolytic agents in pleural cavity; however, it seems related with a delay in resolution, increased cost, and increased complications in trauma patients" 1
This is a critical point—if thrombolytics (which break down clots) cause problems in hemothorax, there's no mechanistic rationale for antifibrinolytics like TXA in the pleural space.
Where TXA IS Indicated in Trauma
TXA has strong evidence for systemic hemorrhage in trauma, not localized pleural bleeding 2, 3:
- CRASH-2 trial (20,211 patients): 1g bolus within 1 hour, then 1g over 8 hours reduces all-cause mortality (RR 0.91) when given within 3 hours of injury 2
- Critical timing: Administration >3 hours post-injury shows NO benefit and may increase hemorrhagic death (RR 1.44) 2
- Indication: Patients with significant hemorrhage (SBP <90 mmHg or HR >110 bpm) or at risk of significant bleeding 2
The 2023 European trauma guidelines and 2025 French emergency medicine guidelines both strongly recommend TXA for systemic trauma hemorrhage, not isolated hemothorax 4, 3.
Clinical Algorithm for Hemothorax with Suspected Bleeding
For Hemodynamically STABLE Patients:
Assess hemothorax size:
Monitor chest tube output:
DO NOT administer TXA for isolated hemothorax—no evidence supports this, and pleural cavity interventions with hemostatic agents are problematic 1
For Hemodynamically UNSTABLE Patients:
Immediate large-bore chest tube drainage regardless of hemothorax size 1
Consider systemic TXA IF patient meets trauma hemorrhage criteria:
Prepare for operative management if:
- Initial output >1500 mL
- Ongoing output >200 mL/h × 3 hours
- Persistent hemodynamic instability 1
Critical Pitfalls to Avoid
Do not confuse systemic TXA indications with local hemothorax management. The evidence for TXA in trauma applies to patients with systemic hemorrhagic shock, not isolated chest tube drainage scenarios. A hemodynamically stable patient with hemothorax being drained does not meet CRASH-2 criteria unless they have concurrent systemic bleeding 2.
Do not delay definitive management (surgery, endovascular procedures) by attempting medical hemostasis with TXA in isolated hemothorax. The 2025 guidelines emphasize complete evacuation and surgical intervention when indicated 1.
Beware of the 3-hour window: If considering TXA for systemic trauma hemorrhage, administration beyond 3 hours post-injury may be harmful 2, 3.
Special Considerations
The only published evidence for TXA in hemothorax consists of two 1991 case reports using intrapleural TXA for malignant mesothelioma-related hemothorax 5—this is not applicable to traumatic hemothorax and represents a completely different clinical scenario with different pathophysiology.
Recent 2025 studies on nebulized TXA focus on hemoptysis (airway bleeding), not hemothorax (pleural space bleeding) 6, 7, 8—these are distinct anatomical compartments with different management approaches.